공고 • Apr 10
Evome Medical Technologies Inc. Announces Resignation of Michael Dalsin as Chairman of the Board of Directors Evome Medical Technologies Inc. announced the resignation of Michael Dalsin as Chairman of the Board of Directors. Mr. Chris Heath will remain on the Board and continues to work to capture shareholder value in the various assets held by Evome. 공고 • Mar 18
Evome Medical Technologies Inc. Announces Board Changes Evome Medical Technologies Inc. announced the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Kashkin, MD will take the role of Vice-Chairman. Bill Garbarini will retain his role as COO while stepping off the Board of Directors. Chris Heath was also appointed as a new Director increasing the size of the Board of Directors from five to six. Mr. Dalsin is best known in Canada as the former Chairman of Convalo Health International Corp. and Patient Home Monitoring Corp., which were both listed on the TSX Venture Exchange. After spinning off its VieMed business unit, PHM uplisted to TSX and listed on Nasdaq under its new name Quipt Home Medical Corp. Mr. Heath was CEO of Convalo and was most recently the CEO of MedBright AI Investments Inc., a CSE listed issuer. 공고 • Nov 26
Evome Medical Technologies Inc. Launches Wholly Owned Distribution Company, Appoints Bill Garbarini Chief Operating Officer Evome Medical Technologies Inc. announced that In November 2024, the Company launched a wholly owned distribution company called Evome Medical Products Company, with a plan to extend its sales and marketing program to include medical therapeutics to complement the current Biodex brands. The company appointed Bill Garbarini Chief Operating Officer. 공고 • Oct 02
Evome Medical Technologies Inc., Annual General Meeting, Nov 08, 2024 Evome Medical Technologies Inc., Annual General Meeting, Nov 08, 2024. Location: shirley, new york United States 공고 • Apr 03
Riddell Sports Group, Inc. acquired Simbex, LLC from Evome Medical Technologies Inc. (TSXV:EVMT) for $3.6 million. Riddell Sports Group, Inc. signed a membership interest purchase agreement Simbex, LLC from Evome Medical Technologies Inc. (TSXV:EVMT) for $3.6 million on April 1, 2024. The gross proceeds will reduce senior debt of Simbex by $824,441 upon closing and acquisition debt of the Evome associated with its acquisition of Biodex by $2,115,559, with the remainder of funds used for transaction costs and debt reduction to subordinated and unsecured creditors.
Riddell Sports Group, Inc. completed the acquisition of Simbex, LLC from Evome Medical Technologies Inc. (TSXV:EVMT) on April 2, 2024. 공고 • Apr 02
Evome Medical Technologies Inc. announced delayed annual 10-K filing On 04/01/2024, Evome Medical Technologies Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공고 • Feb 15
Evome Medical Technologies Inc. Announces Board Changes Evome Medical Technologies Inc. announced the appointment of two senior healthcare executives to its Board of Directors.? Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive ?member of the Board of Directors.? Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors. In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter. 공고 • Feb 03
Evome Medical Technologies Inc. Announces Change of Principal Accounting Officer January 22, 2024, Natalia Vakhitova notified the Board of Directors of Evome Medical Technologies Inc. of her intention to resign as the company's Principal Accounting Officer and Chief Financial Officer effective on January 22, 2024. Ms. Vakhitova did not advise the Company of any disagreement with the company on any matter relating to its operations, policies or practices, including accounting principles and practices. On January 30, 2024, the Board appointed Cherine Pottinger-Harris as the company's Principal Accounting Officer and interim Chief Financial Officer. Prior to joining the Company, from March 2017 to December 2023, Ms. Pottinger-Harris, 43 years old, held the position of Financial Controller at iNECTA, LLC. Ms. Pottinger-Harris was Accounting Manager at D-VAC Sales Inc., from November 2017 to May 2020. Overall, Ms. Pottinger-Harris has over 20 years' experience in accounting and tax. 공고 • Jan 18
Salona Global Medical Device Corporation Announces Leslie Cross Retires from its Board of Directors Salona Global Medical Device Corporation announced Leslie Cross retiring from the Board of Directors. 공고 • Jan 11
Salona Global Medical Device Corporation Announces Resignation of Kyle L. Wilks as Board of Directors Salona Global Medical Device Corporation announced resignation of Kyle L. Wilks as Board of Directors of the company. 공고 • Dec 19
Salona Global Medical Device Corporafion Announces the Debut of the Biodex Reac Five Step Trainer Salona Global Medical Device Corporafion announced the debut of the Biodex Reacfive Step Trainer ("RST"): A revolufionary medical device that combines Biodex Rehab's industry leading gait trainer plafform with a clinically proven perturbafion training system. There is a crifical need for a proacfive approach to fall prevenfion as the world's populafion is aging1. One in three people over the age of 65 experience at least one fall each year and those falls are the leading cause of fatal and nonfatal injuries in older adults2. The RST can help by retraining the neuromuscular system to respond when a person becomes off balance, with the aim of creafing muscle memory when recovering from a trip or slip in a controlled environment. The Company plans to launch the product in the United States at the American Physical Therapy Associafion, Combined Secfions Meefing in Boston on February 15th - 17th, 2024. Available for shipment to customers globally in 2024, the RST medical device further extends the Biodex insfitufional grade technology and intellectual property to the 48,000+ physical therapy rehabilitafion centers and the approximately 30,600+ independent living communifies in the United States alone. Addifionally, the Company is engaging Limmi, a healthcare arfificial intelligence plafform company, to develop predicfive capabilifies for the RST using machine learning from data collected by the device for each individual pafient. 공고 • Nov 21
Salona Global Medical Device Corporation Showcases Biodex Products at Medica Trade Fair in Dusseldorf, Germany; Expanding Access to International Markets Salona Global Medical Device Corporation announced its attendance at Medica 2023 which is held annually in Dusseldorf, Germany. Being one of the premier events in the medical industry around the globe it allows the Company to showcase its products to the industry professionals and connect with potential customers and distributors/strategic partners abroad. CEO Mike Seckler will host a series of events and meetings with the aim of increasing access to untapped international markets for the Company's Biodex Rehab line of medical devices and its Mio-Guard line of medical and athletic supplies. The Company's Biodex Rehab and Mio-Guard divisions are moving forward with collaborating in providing comprehensive services to physical therapy and sports rehabilitation clinics. While Biodex Rehab continues its focus on delivering science-based solutions for rehabilitation exercise and injury recovery segment, Mio-Guard serves as a reliable supplier of sports medicine supplies. Together, they will excel in offering an integrated approach to support the diverse needs of clinics in the field of Physical Medicine. 공고 • Nov 18
Salona Global Medical Device Corporation to Debut an Entire Next Generation Line of Products Salona Global Medical Device Corporafion announced the debut of the Biodex SpaceTek Knee Device: A revolutionary, portable medical device for treating patients with knee replacements and knee injuries. The Company's intention is to submit an application for approval of the SpaceTek Knee Device with the U.S. Food and Drug Administration (the "FDA") in early 2024. The SpaceTek Knee Device is to be offered exclusively by Biodex Medical Systems Inc. (Biodex), and its price point is meant to democratize the Biodex institutional grade technology and intellectual property to physical therapy chiropractic centers in the United States. Because of its compact size and price point, this product is designed to expand the current market for Biodex products. The SpaceTek Knee Device is portable, affordable and can be used in several locations depending on demand within a small clinic with the entire dynamometer and electronics packaged in a case weighing less than 70lbs. The SpaceTek Knee Device was co-developed in collaboration with the National Aeronautics and Space Administration (NASA) for use in outer space based on market leading technology available on the Biodex S4 (S4) isokinetic machine with dynamometers. As the flagship product for Biodex, the S4 was created to treat knees, shoulders and other joints. However, because of its complexity and size, it has a large price tag and requires a trained expert to operate, historically limiting Biodex sales primarily to hospitals, universities, research centers, and sports teams. The company has built four prototypes which are expected to be available to the public in 2024 and are being used by Japanese, European and American distributors to finalize marketing and sales plans for 2024. 공고 • Oct 26
Salona Global Medical Device Corporation Announces Resignation of Dennis Nelson as Chief Accounting Officer and Treasurer Salona Global Medical Device Corporation announced On October 17, 2023, Dennis Nelson, the Company's Chief Financial Officer, Chief Accounting Officer and Treasurer, informed the Company of his resignation effective on October 17, 2023. 공고 • Jul 26
Salona Global Medical Device Corporation Appoints Mike Seckler as Permanent CEO Salona Global Medical Device Corporation announced Mr. Mike Seckler has moved from interim CEO to permanent CEO. 공고 • Jun 27
Salona Global Medical Device Corporation, Annual General Meeting, Aug 11, 2023 Salona Global Medical Device Corporation, Annual General Meeting, Aug 11, 2023. 공고 • Jun 15
Salona Global Appoints Michael Seckler, as Interim CEO Salona Global Medical Device Corporation announced the appointment of Michael Seckler as interim CEO, effective June 13, 2023. Mr. Seckler has a long and successful track record as a senior executive of Ferring Pharmaceuticals, a multi-billion dollar company based in Switzerland, where he was the General Manager of its Canadian subsidiary before being promoted to Vice President of Global Marketing and Corporate Communications. He was most recently a senior executive of FerGene, a Ferring subsidiary focused on gene therapy. With the addition of Lana Newishy as Vice Chair of the Board, the Company has completed its goal of adjusting the management team with a focus on cash flow and debt service as a priority. Mr. Faulstick remains a non-executive director of the Board. In connection with his appointment as interim CEO, Mr. Seckler has been granted options under the Company’s Stock Option Plan to purchase up to 250,000 common shares, vesting equally over a three year period, with a term of five years and an exercise price of $0.25. The options and underlying common shares are subject to a four month and one day hold period pursuant to the TSX Venture Exchange. 공고 • May 26
Salona Global Announces Appointment of Lana Newishy to Its Board of Directors as Executive Vice Chair Salona Global Medical Device Corporation announced the appointment of Lana Newishy to its Board of Directors as Executive Vice Chair, effective May 24, 2023. Ms. Newishy is the former CFO of American Express Corporate Card Canada and most recently served as a senior executive in the Chief of Staff Office for the Global Supply Chain Strategy & Transformation group of The Estee Lauder Companies Inc. 공고 • May 17
Salona Global Medical Device Corporation (TSXV:SGMD) acquired Arrowhead Medical, LLC for $0.85 million. Salona Global Medical Device Corporation (TSXV:SGMD) acquired Arrowhead Medical, LLC for $0.85 million on May 15, 2023. Pursuant to the agreement, the purchase price for the ownership interests in Arrowhead Medical, LLC consisted of the issuance of 1 million shares of its Class A common stock to the seller, the assumption of approximately $250,000 in bank debt under Arrowhead’s existing asset based line of credit, and an agreement to pay the seller a contingent earn-out equal to one share of Class A common stock for each $1 of EBITDA generated by the Arrowhead business over the two year period following the closing date, not to exceed a maximum of 2 million Class A shares. Based on its unaudited financial results, Arrowhead’s sales in calendar year 2022 were approximately $3.5 million, with gross profit of approximately 32%.
Salona Global Medical Device Corporation (TSXV:SGMD) completed the acquisition of Arrowhead Medical, LLC on May 15, 2023. 공고 • May 12
Salona Global Medical Device Corporation to Report Q1, 2023 Results on May 16, 2023 Salona Global Medical Device Corporation announced that they will report Q1, 2023 results on May 16, 2023 공고 • Jan 13
Salona Global Medical Device Corporation to Report Q3, 2023 Results on Jan 17, 2023 Salona Global Medical Device Corporation announced that they will report Q3, 2023 results on Jan 17, 2023 
